Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57.
Naslov
Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57.
Opis
J. Rožić, Z. Gojković, S. Jungić, I. Rakita, Ž. Vranješ, R. Rašeta, G. Marić, M. Vještica, S. Mijatović, P. Dašić, M. Vižin, Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57., This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011., 2011.
Identifikator
/unibl/sci/idNaucniRad:8551
Tip
Pronađite slične unoseArticle
Datum
Bibliografski citat
J. Rožić, Z. Gojković, S. Jungić, I. Rakita, Ž. Vranješ, R. Rašeta, G. Marić, M. Vještica, S. Mijatović, P. Dašić, M. Vižin, Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57., This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011., 2011
Prezentovano
This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011.
Lista autora
Position: 1319 (41 views)